# IPS Bio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ips-bio-co

- Industry: Biotechnology
- Headquarters: Gyeonggi-do, South Korea
- Website: www.ipsbio.com
- Total disclosed funding: $7.1M
- Latest round: Series A (May 17, 2021)
- Investors on record: 3

## About

Founded in 2019 by Song Ji-hwan (CEO), and based in Gyeonggi-do, South Korea, IPS Bio Co., Ltd. operates as a biotechnology company that engages in the research and development of stem cell solutions and therapies aimed at treating rare diseases. In May 2021, IPS Bio Co., Ltd. raised KRW 8 billion in Series A funding led by investor POSCO Capital, with participation from Kolon Investment and LSK Investment. The firm’s partners include CHDI Foundation, Roche, the University of Rochester Medical Center, Novartis, etc. 



The company offers novel treatments and therapies for intractable and degenerative neurological diseases using iPS stem cells. The company develops cell therapies and small molecules to treat diseases like strokes, Huntington’s disease, Alzheimer’s, etc.

## Funding rounds

- Series A, May 17, 2021, $7.1M — Posco Investment, Kolon Investment, LSK Investment

## Investors

- Posco Investment (https://capitalatlas.ai/funds/posco-investment) — Series A
- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series A
- LSK Investment (https://capitalatlas.ai/funds/lsk-investment) — Series A